ArriVent BioPharma, Inc. (AVBP)
- Previous Close
15.54 - Open
16.00 - Bid 15.39 x 200
- Ask 15.65 x 100
- Day's Range
15.40 - 16.47 - 52 Week Range
14.35 - 25.95 - Volume
53,086 - Avg. Volume
198,398 - Market Cap (intraday)
517.144M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.50
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
www.arrivent.comRecent News: AVBP
Compare To: AVBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVBP
Valuation Measures
Market Cap
517.14M
Enterprise Value
367.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.92
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.95%
Return on Equity (ttm)
-42.57%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-69.33M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
150.39M
Total Debt/Equity (mrq)
0.21%
Levered Free Cash Flow (ttm)
-32.8M